SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 7, 2000
----------------
Oncor, Inc.
------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Maryland
------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-16177 52-1310084
- ------------------------------ ---------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
15200 Shady Grove Road, Rockville, Maryland 20850
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(301) 527-2222
------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N.A.
------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 3. Bankruptcy or Receivership
On April 7, 2000, the Second Amended Liquidating Chapter 11 Plans (the "Plans")
of Oncor, Inc. (the "Company") and its wholly-owned subsidiary, Codon
Pharmaceuticals, Inc. ("Codon") became effective. An order confirming the Plans,
pursuant to section 1129 of the Bankruptcy Code, dated February 29, 2000, had
previously been entered by the United States Bankruptcy Court for the District
of Delaware on March 7, 2000. The Company and Codon originally filed voluntary
petitions for relief under Chapter 11 of the United States Code in the United
States Bankruptcy Court for the District of Delaware on February 26, 1999.
The Company's Plan provides for the liquidation of all assets of the Company and
the cancellation of all equity interests in the Company. In addition, the Plan
provides for the payment of administrative expenses and priority tax claims in
cash in full, and for the partial payments of all other claims (other than those
related to the Company's equity interests).
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
99.1 Confirmation Order pursuant to section 1129 of the
Bankruptcy Code, dated February 29, 2000, entered by the United States
Bankruptcy Court for the District of Delaware on March 7, 2000, confirming
Oncor, Inc.'s and Codon Pharmaceuticals, Inc.'s Second Amended Liquidating
Chapter 11 Plans (In re: Codon Pharmaceuticals, Inc. and Oncor, Inc., Case No.
99-436).
99.2 Press release dated April 13, 2000 announcing that on
April 7, 2000 the Second Amended Liquidating Chapter 11 Plan of Oncor, Inc.
became effective.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Oncor, Inc.
-----------------------------------------
(Registrant)
By: /s/ Joseph R. Shaya
----------------------------------
Name: Joseph R. Shaya
Title: Acting President and Chief Executive
Officer
Dated: April 14, 2000